Treatment of methamphetamine-induced psychosis: A double-blind randomized controlled trial comparing haloperidol and quetiapine

Psychopharmacology

Volumn 231, Issue 16, 2014, Pages 3099-3108

  Verachai, Viroj ^a   Rukngan, Warangkana ^a   Chawanakrasaesin, Kachornwan ^a   Nilaban, Sumnao ^a   Suwanmajo, Somporn ^a   Thanateerabunjong, Rossukon ^a   Kaewkungwal, Jaranit ^b   Kalayasiri, Rasmon ^c  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Haloperidol; Methamphetamine; Psychosis; Quetiapine

Indexed keywords

HALOPERIDOL; METHAMPHETAMINE; QUETIAPINE; CENTRAL STIMULANT AGENT; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; AKATHISIA; ARTICLE; BEDTIME DOSAGE; BLURRED VISION; CLINICAL PROTOCOL; CONSTIPATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; DYSTONIA; FEMALE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SEDATION; SURVIVAL RATE; TARDIVE DYSKINESIA; URINE RETENTION; XEROSTOMIA; ADOLESCENT; COMPARATIVE STUDY; ONSET AGE; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; PSYCHOSES, SUBSTANCE-INDUCED; SOCIOECONOMICS; SURVIVAL; YOUNG ADULT;

ADOLESCENT; ADULT; AGE OF ONSET; ANTIPSYCHOTIC AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; MALE; METHAMPHETAMINE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOSES, SUBSTANCE-INDUCED; SOCIOECONOMIC FACTORS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84904964172     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3485-6     Document Type: Article

References (48)

1. Berk M, Brook S, Trandafir AI (1999) A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial. Int Clin Psychopharmacol 14:177-180
2. Booij J, van Amelsvoort T (2012) Imaging as a tool to investigate psychoses and antipsychotics. Handb Exp Pharmacol 212:299-337
3. Bramnes JG, Gundersen O, Guterstam J, Rognli EB, Konstenius M, Loberg EM, Medhus S, Tanum L, Franck J (2012) Amphetamine-induced psychosis - a separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC Psychiatry 2012:221
4. Brown ES, Nejtek VA, Perantie DC, Bobadilla L (2002) Quetiapine in bipolar disorder and cocaine dependence. Bipolar Disord 4:406-411
5. Brown ES, Nejtek VA, Perantie DC, Rajan Thomas N, Rush AJ (2003) Cocaine and amphetamine use in patients with psychiatric illness: a randomized trial of typical antipsychotic continuation or discontinuation. J Clin Psychopharmacol 23:384-388
6. Carvalho M, Carmo H, Costa VM, Capela JP, Pontes H, Remiao F, Carvalho F, Bastos MD (2012) Toxicity of amphetamines: an update. Arch Toxicol 6:6
7. Connell PH (1958) Amphetamine psychosis. Oxford University Press, London
8. Crews FT, Boettiger CA (2009) Impulsivity, frontal lobes and risk for addiction. Pharmacol Biochem Behav 93:237-247
9. Crossley NA, Constante M, McGuire P, Power P (2010) Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br J Psychiatry 196:434-439
10. Curran C, Byrappa N, McBride A (2004) Stimulant psychosis: systematic review. Br J Psychiatry 185:196-204
11. Dossenbach M, Erol A, el Mahfoud Kessaci M, Shasheen MO, Sunbol MM, Boland J, Hodge A, O'Halloran RA, Bitter I, IC-SOHO Study Group (2004) Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry 65:312-321
12. Horacek J, Budenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Höschl C (2006) Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 20:389-409
13. Kalayasiri R, Mutirangura A, Verachai V, Gelernter J, Malison RT (2009) Risk factors for methamphetamine-induced paranoia and latency of symptom onset in a Thai drug treatment cohort. Asian Biomed 3:635-643
14. Kariya S, Isozaki S, Masubuchi Y, Suzuki T, Narimatsu S (1995) Possible pharmacokinetic and pharmacodynamic factors affecting parkinsonism inducement by cinnarizine and flunarizine. Biochem Pharmacol 50:1645-1650
15. Kennedy A, Wood AE, Saxon AJ, Malte C, Harvey M, Jurik J, Kilzieh N, Lofgreen C, Tapp A (2008) Quetiapine for the treatment of cocaine dependence: an open-label trial. J Clin Psychopharmacol 28:221-224
16. Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, Srisurapanont M, Kissling W, Leucht S (2010) Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. doi: 10.1002/14651858.CD006625. pub3
17. Kuroki T, Nagao N, Nakahara T (2008) Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog Brain Res 172:199-212
18. Leelahanaj T, Kongsakon R, Netrakom P (2005) A 4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis. J Med Assoc Thail 88:S43-S52
19. McIntyre RS, Brecher M, Paulsson B, Huizar K, Mullen J (2005) Quetiapine or haloperidol as monotherapy for bipolar mania - a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 15:573-585
20. McKetin R, Ross J, Kelly E, Baker A, Lee N, Lubman DI, Mattick R (2008) Characteristics and harms associated with injecting versus smoking methamphetamine among methamphetamine treatment entrants. Drug Alcohol Rev 27:277-285
21. Martinotti G, Andreoli S, Di Nicola M, Di Giannantonio M, Sarchiapone M, Janiri L (2008) Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics. Hum Psychopharmacol 23:417-424
22. Meltzer HY, McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233-255
23. Meltzer HY, Sumiyoshi T (2008) Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia? Behav Brain Res 195:98-102
24. Nejtek VA, Avila M, Chen LA, Zielinski T, Djokovic M, Podawiltz A, Kaiser K, Bae S, Rush AJ (2008) Do atypical antipsychotics effectively treat co-occurring bipolar disorder and stimulant dependence? A randomized, double-blind trial. J Clin Psychiatry 69:1257-1266
25. Nichaikovit T, Uneanong S, Kessawai D, Thomyangkoon P (2000) The Thai version of the Positive and Negative Syndrome Scale (PANSS) for schizophrenia: criterion validity and interrater reliability. J Med Assoc Thail 83:646-651
26. Nishikawa T, Mataga N, Takashima M, Toru M (1983) Behavioral sensitization and relative hyperresponsiveness of striatal and limbic dopaminergic neurons after repeated methamphetamine treatment. Eur J Pharmacol 88:195-203
27. Ozbilen M, Adams CE, Marley J (2012) Anticholinergic effects of oral antipsychotic drugs of typicals versus atypicals over medium- and long-term: systematic review and meta-analysis. Curr Med Chem 19:5214-5218
28. Potvin S, Stip E, Roy JY (2003) Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses. Int Clin Psychopharmacol 18:121-132
29. Ray LA, Chin PF, Heydari A, Miotto K (2011) A human laboratory study of the effects of quetiapine on subjective intoxication and alcohol craving. Psychopharmacology (Berlin) 217:341-351
30. Rizkallah E, Stip E, Zhornitsky S, Pampoulova T, Gendron A, Rompré PP, Chiasson JP, Potvin S (2010) Clinical evolution of substance use disorder patients during treatment with quetiapine: a 12-week, open-label, naturalistic trial. Expert Opin Pharmacother 11:2947-2951
31. Sato M, Chen CC, Akiyama K, Otsuki S (1983) Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biol Psychiatry 18:429-440
32. Sattar SP, Bhatia SC, Petty F (2004) Potential benefits of quetiapine in the treatment of substance dependence disorders. J Psychiatry Neurosci 29:452-457
33. Sayers SL, Campbell EC, Kondrich J, Mann SC, Cornish J, O'Brien C, Caroff SN (2005) Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J Nerv Ment Dis 193:379-386
34. Seeman P (2002) Atypical antipsychotics: mechanism of action. Can J Psychiatry 47:27-38
35. Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, Yoshikawa E, Futatsubashi M, Takei N, Mori N (2001) Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 158:1206-1214
36. Shoptaw SJ, Kao U, Ling W (2009) Treatment for amphetamine psychosis. Cochrane Database Syst Rev. doi: 10.1002/14651858.CD003026.pub3
37. Smelson DA, Ziedonis D, Williams J, Losonczy MF, Williams J, Steinberg ML, Kaune M (2006) The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report. J Clin Psychopharmacol 26:9-12
38. Srisurapanont M, Ali R, Marsden J, Sunga A, Wada K, Monteiro M (2003) Psychotic symptoms in methamphetamine psychotic in-patients. Int J Neuropsychopharmacol 6:347-352
39. Srisurapanont M, Kittirattanapaiboon P, Jarusuraisin N (2001) Treatment for amphetamine psychosis. Cochrane Database Syst Rev. doi: 10.1002/14651858. CD003026
40. Suttajit S, Srisurapanont M, Xia J, Suttajit S, Maneeton B, Maneeton N (2013) Quetiapine versus typical antipsychotic medications for schizophrenia. Cochrane Database Syst Rev. doi: 10.1002/14651858.CD007815.pub2
41. Thanyarak Institute (2012) Substance statistics at Thanyarak Institute (in Thai). Retrieved from http://www.thanyarak.go.th
42. Tillmann HC, Sharpe N, Sponer G, Wehling M (2001) Does intention-to-treat analysis answer all questions in long-term mortality trials? Considerations on the basis of the ANZ trial. Int J Clin Pharmacol Ther 39:205-212
43. Timdahl K, Carlsson A, Stening G (2007) An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms. Hum Psychopharmacol 22:315-325
44. Tong J, Ross BM, Schmunk GA, Peretti FJ, Kalasinsky KS, Furukawa Y, Ang LC, Aiken SS, Wickham DJ, Kish SJ (2003) Decreased striatal dopamine D1 receptor-stimulated adenylyl cyclase activity in human methamphetamine users. Am J Psychiatry 160:896-903
45. UNODC (2012) World drug report 2012 (United Nations publication), Sales No. E.12.XI.1
46. Wang GJ, Smith L, Volkow ND, Telang F, Logan J, Tomasi D, Wong CT, Hoffman W, Jayne M, Alia-Klein N, Thanos P, Fowler JS (2012) Decreased dopamine activity predicts relapse in methamphetamine abusers. Mol Psychiatry 17:918-925
47. Yui K, Ishiguro T, Goto K, Ikemoto S, Kamata Y (1999) Spontaneous recurrence of methampetamine psychosis: increased sensitivity to stress associated with noradrenergic hyperactivity and dopaminergic change. Eur Arch Psychiatry Clin Neurosci 249:103-111
48. Zhornitsky S, Rizkallah E, Pampoulova T, Chiasson JP, Stip E, Rompre PP, Potvin S (2010) Antipsychotic agents for the treatment of substance use disorders in patients with and without comorbid psychosis. J Clin Psychiatry 30:417-424